Novel antibiotic to treat MRSA and VRE infections shows promising results in Phase 2 clinical trials

Novel drug candidate, MRX-I, an oral oxazolidinone showed positive top-line results from the first Phase 2 clinical study in China, according to biopharmaceutical company, MicuRx Pharmaceuticals, Inc. today. "These clinical data demonstrate that MRX-I has the potential to be a safe and effective antibiotic for a broad range of infections, including those that are multidrug-resistant," said Dr. Zhengyu Yuan, president ["]